At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed adenocarcinoma of colon or rectum unresectable by surgery (stage IV)
- ✓Measurable disease
- ✓ECOG performance status ≤1
- ✓Life expectancy >3 months
- ✕Known brain metastases
- ✕Radiotherapy within 4 weeks prior to entry or incomplete recovery from prior radiotherapy
- ✕Concurrent investigational agents
- ✕History of allergic reactions to similar agents used in study
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer
In Brief
A Phase 2 clinical trial evaluating cetuximab, bevacizumab, and 3 other interventions for Adenocarcinoma of the Rectum and 6 related conditions. Completed, enrolled 66 participants across 1 site.
Detailed Summary
Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab and cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of colorectal cancer by blocking blood flow to the tumor. Giving combination chemotherapy together with bevacizumab and cetuximab may kill more tumor cells. This phase II trial is studying how well giving combination chemotherapy together with bevacizumab and cetuximab works in treating patients with stage IV colorectal cancer that cannot be removed by surgery.
Study Details
Timeline
Interventions
Given IV
Given IV
Given IV
Given IV
Given IV